Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver.(Hepatology 2018;67:1768-1783).
|
29140550 |
2018 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of Pgrmc1 increased mature SREBP-1 protein level, suggesting that induction of hepatic steatosis in Pgrmc1 KO mice might be triggered by de novo lipogenesis.
|
30356113 |
2018 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN).
|
28449683 |
2017 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The improvement of hepatic steatosis observed in DIO-treated mice was associated with a decrease in the hepatic content of SREBP-1, a transcription factor involved in de novo lipogenesis.
|
28557705 |
2017 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
|
28483554 |
2017 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway.
|
25087956 |
2014 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
CTD_human |
A simple transcriptomic signature able to predict drug-induced hepatic steatosis.
|
24469900 |
2014 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using miR-33(-/-)Srebf1(+/-) mice, we demonstrate that SREBP-1 is a target of miR-33 and that the mechanisms leading to obesity and liver steatosis in miR-33(-/-) mice involve enhanced expression of SREBP-1.
|
24300912 |
2013 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study investigated the role of the adenosine monophosphate-activated protein kinase (AMPK)-sterol regulatory element-binding protein-1 (SREBP-1) pathway in the OA-induced fatty liver.
|
21757781 |
2011 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gentiana manshurica Kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation.
|
21105651 |
2010 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
They also show that the SREBP1-mediated induction of hepatic steatosis in ob/ob mice requires Gpat1.
|
20200319 |
2010 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.
|
18360697 |
2008 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, overexpression of PPARdelta by intravenous infection with the PPARdelta adenovirus induced the expression of Insig-1, suppressed SREBP-1 activation, and, consequently, ameliorated hepatic steatosis in obese db/db mice.
|
18627005 |
2008 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.
|
17484888 |
2007 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A new transgenic rat model of hepatic steatosis and the metabolic syndrome.
|
15809359 |
2005 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively active SREBP-1-overexpressing mice had fatty livers without hepatomegaly, hypoglycemia, or hypertriglyceridemia.
|
14633850 |
2003 |